EP0169672A1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Method for producing transgenic animals
Assignee: Harvard University
•
Filing: 1985-06-24
•
Granted: —
•
Expires: 2005-06-24
Abstract
Abstract A method for producing a transgenic eucaryotic animal having an increased probability of developing neoplasms, said method comprising introducing into an animal embryo an activated oncogene sequence. The animal may be used in testing a material suspected of being carcinogenic or of conferring protection against carcinogens.
Inventors
- 👤 Philip Leder
- 👤 Timothy A. Stewart
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-03 12:23
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/63; C12N15/79; C12N15/85; C12N15/8509; A; A01; A01K; A01K67/00; A01K67/027; A01K67/0275; C07; C07K; C07K14/00; C07K14/005; G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/5005; G01N33/5008; G01N33/5014; G01N33/5017; G01N33/53; G01N33/575; G01N33/57575; A01K2217/00; A01K2217/05; A01K2217/20; A01K2227/00; A01K2227/10; A01K2227/105; A01K2267/00; A01K2267/03; A01K2267/0331; A01K2267/0393; C12N2740/00; C12N2740/00011; C12N2740/10011; C12N2740/11011; C12N2740/11022
Claims Analysis
Total Claims: 20
Claim 1
Independent Claim
27 words
A method for producing a transgenic eucaryotic animal having an increased probability of developing neoplasms, said method comprising introducing into an animal embyro an activated oncogene sequence.
Claim 2
Independent Claim
27 words
A method for producing a transgenic eucaryotic animal having an increased probability of developing neoplasms, said method comprising introducing into an animal embyro an activated oncogene sequence.
Claim 3
Dependent Claim
28 words
A method as claimed in claim 1 wherein the chromosome of the animal includes an endogenous coding sequence substantially the same as the coding sequence of the oncogene.
Claim 4
Dependent Claim
31 words
A method as claimed in claim 2 wherein said oncogene sequence is integrated into a chromosome of said animal at a site different from the location of said endogenous coding sequence.
Claim 5
Dependent Claim
37 words
A method as claimed in claim 2 or claim 3 wherein transcription of said oncogene sequence is under the control of a promoter sequence different from the promoter sequence controlling the transcription of said endogenous coding sequence.
Claim 6
Independent Claim
24 words
A method as claimed in any one of claims 2 to 4 wherein said promoter sequence controlling transcription of said oncogene sequence is inducible.
Claim 7
Independent Claim
34 words
A method as claimed in any one of claims 1 to 4 wherein said activated oncogene sequence comprises a fused gene comprising an oncogene sequence fused to an activating viral or synthetic promotor sequence.
Claim 8
Dependent Claim
24 words
A method as claimed in claim 6 wherein said viral promoter sequence comprises a sequence selected either from an MMTV or an RSV promoter.
Claim 9
Independent Claim
24 words
A method as claimed in any one of claims 1 to 7 wherein said oncogene sequence comprises a coding sequence of a c-myc gene.
Claim 10
Independent Claim
61 words
A method as claimed in any one of claims 1 to 7 wherein said activated oncogene sequence comprises a DNA sequence selected from the ocogenes src, yes, fps, abl, ros, fgr, erbB, fms, mos, raf, Ha-ras-1, Ki-ras 2, Ki-ras 1. myc, myb, fos, ski, rel, sis, N-myc, N-ras, Blym, mam, neu, erbAl, ra-ras, mht-myc, myc, myb-ets, raf-2, raf-1. Ha-ras-2, or erbB.
Claim 11
Independent Claim
24 words
A method as claimed in any one of claims 1 to 8 wherein said activated oncogene is provided in the form of a plasmid.
Claim 12
Dependent Claim
14 words
A plasmid selected from the group comprising plasmids ATCC 39745, 39746, 39747, 39748, 39749.
Claim 13
Dependent Claim
14 words
A plasmid selected from the group comprising plasmids ATCC 39745, 39746, 39747, 39748, 39749.
Claim 14
Dependent Claim
22 words
A method as claimed in claim 1 wherein the activated oncogene sequence is derived from a plasmid as defined in claim 11.
Claim 15
Dependent Claim
28 words
A method as claimed in claim 1 which comprises injecting into the male pronucleus of a fertilized one-cell mouse egg a linearized plasmid as defined in claim 11.
Claim 16
Independent Claim
40 words
A method of testing a material suspected of being a carcinogen which comprises exposing an animal produced according to the method of any one of claims 1 to 13 to said material and detecting neoplasms as an indication of carcinogenicity.
Claim 17
Independent Claim
57 words
A method of testing a material suspected of conferring protection against the development of neoplasms, said method comprising treating an animal produced according to the methods of any one of claims 1 to 13 with said material and detecting a reduced incidence of development of neoplasms, compared to an untreated animal, as an indication of said protection.
Claim 18
Dependent Claim
30 words
A method as claimed in claim 15, further comprising exposing said treated and untreated animals to a carcinogen prior to, after or simultaneously with treating said animals with said material.
Claim 19
Dependent Claim
51 words
A transgenic non-human eucaryotic animal whose germ cells and somatic cells contain an activated oncogene sequence introduced into said animal, or an ancestor of said animal, at an embryonic stage, said oncogene optionally being further defined according to any one of claims 3 to 10, said animal preferably being a rodent.
Claim 20
Dependent Claim
24 words
A chromosome of an animal as claimed in claim 17, which comprises an oncogene as defined in any one of claims 3 to 10.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.